Newly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature

Aseem Kumar Tiwari, Dinesh Arora, Ravi C. Dara, Pranav Dorwal, Nitin Sood, Ruchira Misra, Sunil Kumar Gupta, Vinmarsh Raina, Ashok Kumar Vaid

Departments of Transfusion Medicine, 1Molecular Genetics and Immunology, 2Medical and Hemato-oncology and 3Paediatric Medical and Hemato-oncology, Medanta - The Medicity, 1Laboratory Services and Transfusion Medicine, Medanta - The Medicity, Gurgaon, Haryana, India

Address for correspondence:
Dr. Aseem Kumar Tiwari,
Department of Transfusion Medicine, Medanta - The Medicity,
Sector-38, Gurgaon - 122 001,
Haryana, India.
E-mail:aseemtwr@yahoo.co.in

ABSTRACT

Background: Hematopoietic progenitor stem cell transplantation (HPSCT) is used as a standard treatment option to improve outcome in hematological and nonhematological disorders. It is important for new HPSCT program to look at its patient outcome data and compare it with the published data to evaluate the efficacy of program. Aims: The aim was to compile and collate the patient outcome data of HPSCT and compare with published reports. Materials and Methods: Patient demographics, indications, stem cell harvest by apheresis, dose collected, infusion, engraftment, and follow-up data were collected from hospital information system from 2010 to 2013 in a tertiary care hospital. HPSCTs were mobilized with granulocyte colony-stimulating factor, and harvests were done on the 5th day. Engraftment was decided for neutrophil when counts were 0.5 × 10^9/L and for platelets when counts were 20 × 10^9/L on two consecutive days without any transfusion support. Results: There were 133 harvests for 95 patients with various disorders; multiple myeloma was most common in autologous and acute lymphoblastic leukemia in allogeneic group. One hundred harvests were done for autologous and 33 for allogeneic HPSCT. In autologous group, of 66 patients, 60 (90.9%) received stem cell infusion at median dose of 4.63 × 10^6 CD34+ cells/kg. Similarly, in allogeneic group, of 29 patients, 27 (93.10%) received infusion at median dose of 5.8 × 10^6 CD34+ cells/kg. 58 (96.9%) patients and 25 (92.6%) engrafted in autologous and allogeneic group, respectively. The median time for neutrophils engraftment was 11 days in autologous group and 12 days in allogeneic group. The median time for platelet engraftment was 11.5 days in autologous group and 13 days in allogeneic group. The 100-day survival rate was 95% (n = 57) in autologous group and 77.8% (n = 21) in allogeneic group. Conclusion: This data analysis shows reasonably good results of HPSCTs with majority of patients surviving at 100-day follow-up. Key words: Follow-up, hematopoietic progenitor stem cell transplants, mortality, peripheral blood stem cells, stem cell transplant program, survival, transplant

INTRODUCTION

Hematopoietic progenitor stem cell transplants (HPSCTs) are an established therapy to treat several benign and malignant disorders, with hematological malignancies being the most common indications for HPSCT.[1–8] High-dose chemotherapy along with autologous HPSCT results in better survival rates and remission as compared with “only” standard multi-agent chemotherapy in multiple myeloma (MM).[9] In other hematological conditions such as acute myeloid leukemia (AML), acute lymphoid leukemia, and Hodgkin’s lymphoma requiring allogeneic HPSCT, such transplants were earlier considered as the second line of treatment.[7–9] However, over the last few years, use of allogeneic HPSCT has become the first line of treatment for these disorders. Many studies on allogeneic HPSCT have recognized the advantages of the transplant procedure in these disorders.[10–17]

As per published data in JAMA 2006,[18] 50,417 transplants were done all over the world comprised 57% of autologous and 43% of allogeneic transplants while in India, only 1540 transplants were done from October 1986 to December 2006 in nine centers across the country, with an average of around 77 transplants per year which works out to be miniscule (0.002%) portion of global transplants pie.[19] Since then, HPSCT has increased several folds with obvious increase in numbers of transplant centers in India as

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Tiwari AK, Arora D, Dara RC, Dorwal P, Sood N, Misra R, et al. Newly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature. Indian J Med Paediatr Oncol 2016;37:168-73.
evident in several published reports from India.\textsuperscript{19-24} We would like to report a single-center experience of patient outcome in autologous and allogeneic transplants including but not limited to 30 and 100 days patient follow-up data. These results have been compared with published data from India.

**MATERIALS AND METHODS**

**New hematopoietic progenitor stem cell transplantation program**

In 2010, the HPSCT program was started at 1000-bedded tertiary care hospital with high efficiency particulate air (HEPA)- filter rooms. The institute organized trained personnel, systems, processes, and all ancillary services for initiating HPSCT program.

**Data collection**

The data were retrieved from hospital information system (HIS) for the 3-year period, 2010–2013. These data included patient and donor epidemiological data, disease condition, chemotherapy regimen, mobilization, harvest data, dose collected, cryopreservation if any, infusion data, engraftment, and follow-up. Data for the patients who succumbed to their illness before stem cell infusion were also collected.

**Chemotherapy**

Chemotherapy and conditioning regimens were given to patients of both groups [Table 1].

**Donor selection (patient-donor and allogeneic donor)**

In autologous patients, the HPSC harvest was done when the patient-donor was in complete remission (minimal residual disease of <0.01% for acute lymphoblastic leukemia [ALL] and <0.1% for AML performed on three-color flow cytometry; FACSCalibur, Becton Dickinson, Heidelberg, Germany).\textsuperscript{25} In allogeneic HPSCT, donor selection was based on human leukocyte antigen (HLA) typing and donor with 6/6 match (HLA A, HLA B, and DRB1) for matched siblings and 10/10 for unmatched unrelated donors (HLA A, B, C, DRB1, and DQB1). All donors underwent mandatory test for infectious disease markers (anti-HIV, anti-hepatitis C virus, anti-hepatitis B core [total], anti-cytomegalovirus [CMV], hepatitis B surface antigen, tests for syphilis and malaria, and CMV polymerase chain reaction). Patient-donors (autologous) and patients (allogeneic) were screened and cleared for transplant after normal liver function tests (LFTs), renal function tests (RFTs), echocardiography, pulmonary function tests, ENT, and dental and psychiatric evaluation. ABO and Rh blood group was done for both donors and recipients.

### Table 1: Chemotherapy and conditioning regimens followed at our center

| Disease  | Diagnosis                        | Total number of patients | Mean age; range | Gender (male:female) | Chemotherapy regimen                      | Conditioning regimen |
|----------|----------------------------------|--------------------------|-----------------|----------------------|------------------------------------------|---------------------|
| Autologous |                                  |                          |                 |                      |                                          |                     |
|          | MM                               | 52                       | 52.4; 21-66     | 33:19                | Bortezomib-dexamethasone                  | Melphalan           |
|          | HL                               | 6                        | 36.5; 13-54     | 6:0                  | NA                                       | BEAM                |
|          | NHL                              | 4                        | 44.7; 33-58     | 3:1                  | NA                                       | BEAM                |
|          | Others                           | 3                        | 32; 20-53       | 3:1                  | Bortezomib-dexamethasone                  | Melphalan           |
|          | MM                               | 52                       | 52.4; 21-66     | 33:19                | Bortezomib-dexamethasone                  | Melphalan           |
|          | HL                               | 6                        | 36.5; 13-54     | 6:0                  | NA                                       | BEAM                |
|          | NHL                              | 4                        | 44.7; 33-58     | 3:1                  | NA                                       | BEAM                |
|          | Others                           | 3                        | 32; 20-53       | 3:1                  | Bortezomib-dexamethasone                  | Melphalan           |
|          | MM                               | 52                       | 52.4; 21-66     | 33:19                | Bortezomib-dexamethasone                  | Melphalan           |
|          | HL                               | 6                        | 36.5; 13-54     | 6:0                  | NA                                       | BEAM                |
|          | NHL                              | 4                        | 44.7; 33-58     | 3:1                  | NA                                       | BEAM                |
|          | Others                           | 3                        | 32; 20-53       | 3:1                  | Bortezomib-dexamethasone                  | Melphalan           |
|          | MM                               | 52                       | 52.4; 21-66     | 33:19                | Bortezomib-dexamethasone                  | Melphalan           |
|          | HL                               | 6                        | 36.5; 13-54     | 6:0                  | NA                                       | BEAM                |
|          | NHL                              | 4                        | 44.7; 33-58     | 3:1                  | NA                                       | BEAM                |
|          | Others                           | 3                        | 32; 20-53       | 3:1                  | Bortezomib-dexamethasone                  | Melphalan           |

MDS – Myelodysplastic syndrome; GCT – Germ cell tumor; CEP – Cisplatin; etoposide; bleomycin; NA – Not available; BEAM – Carmustine; etoposide; cytarabine; melphalan; ATG – Antitymocyte globulin.
Mobilization and harvest
Mobilization was done using granulocyte colony-stimulating factor at a dose of 10 µg/kg body weight in two divided doses given subcutaneously for 4 days and in a single dose on the 5th day before harvest. Harvest was carried out on the 5th day. An 18-gauge double-lumen hemodialysis type intravenous catheter in jugular or femoral vein was used for venous access in adults (8/11 F double-lumen in children below 12 years). All procedures were done by apheresis machine (COM.TEC® Fresenius Kabi, Germany). The P1YA kit was used, and the collection program was set to auto-mononuclear cells. A dose of 5–6 million CD34+ cells/kg body weight was targeted with minimum of 2 million CD34+ cells/kg body weight for both groups. A dose of <2 million CD34+ cells/kg body weight was considered as “inadequate dose.”

Enumeration
The CD34+ cells enumeration was done on FACSCalibur. CD34+ count was done before harvest (to enter the precount value of stem cell in apheresis machine) and for the product (to know the final dose in collection bag). The enumeration was done as per the standard International Society of Haematology and Graft Engineering protocol.

Cryopreservation
In some cases, HPSCs were harvested and cryopreserved. For cryopreservation procedure, volume depletion of product was done by removing red blood cells and plasma. In 100 ml bag, 50 ml of product was mixed with 50 ml cocktail of saline, albumin dimethyl sulfoxide, and dextran-40. Storage was done in liquid nitrogen (−196°C).

Stem cell infusion
The HPSCT infusion was carried out in rooms with high-efficiency particulate air (HEPA) filters under positive pressure. The infusion was done through a central line (Hickman), and all the patients were prophylactically hydrated and given antihistamines before infusion. They were monitored for blood pressure, pulse, respiratory rate, and oxygen saturation during the procedure. Reverse barrier nursing was practiced according to the institutional protocol. Patient monitoring was done for critical parameters at defined frequency (complete blood counts and electrolytes once a day; LFT, RFT, and blood glucose twice a week; blood culture as and when deemed necessary). Antimicrobial prophylaxis included levofloxacin, fluconazole, and acyclovir.

Engraftment
Neutrophil engraftment was defined as absolute neutrophil count of 500 cells/mm3 (0.5 × 10^9/L) or greater for two consecutive days. Platelet engraftment was defined by the achievement of a continued platelet count of 20,000/mm3 (20 × 10^9/L) or greater for two consecutive days, at least 7 days from the last platelet infusion. Those who did not engraft up till the 28th day were considered as “engraftment failure.” Standard protocols were followed in deciding blood component transfusion for all ABO-compatible transplants and major, minor, and bidirectional ABO-incompatible transplants. The threshold for initiating RBC transfusion was hemoglobin of 7 g/dl and 10,000/µl platelet transfusions. After successful engraftment, patients were shifted to non-HEPA rooms and discharged once they were clinically stable.

Follow-up
Patients were followed up after discharge daily for 1 week, every alternate day for 2 weeks, then weekly till posttransplant day 100. Mortality data of all patients at 30 and 100 days were also collected. The follow-up included engraftment failure, complications, transplant-related death, and all-causes death.

Statistical analysis
The data were censored on December 31, 2013. Data were analyzed and mean, median, and range were calculated using Microsoft Excel software and SPSS Statistical Package for the Social Sciences version 20 (SPSS Inc., Chicago, IL, USA).

Ethical approval
No permission from the Ethics Committee was required since the analysis was limited to retrospective HIS data. Personal identifiers such as name were not used.

RESULTS
There were 133 harvests for 95 patients (autologous: 66, allogeneic: 29) with various disorders; MM was most common in autologous and ALL in allogeneic group [Table 1]. There were 67 men and 28 women, with the mean age of 40 years. Chemotherapy and conditioning regimens were used as per the patient’s disease condition [Table 1].

In autologous group, 54 (81.8%) patient-donors required only one apheresis session while 12 (18.2%) patient-donors required more than one apheresis session (mean = 1.52). In allogeneic group, 26 (89.6%) donors required one session and three (10.4%) required two or more apheresis sessions (mean = 1.14) to obtain adequate dose.

Of 66 patients in autologous group, 62 (93.9%) were transplanted. Four (6.1%) patients succumbed to their disease before HPSC’s infusion. Twelve patients in autologous group received thawed HPSCs product as it was cryopreserved immediately after harvest. Similarly, in allogeneic group, of 29 patients, 27 (93.10%) were transplanted. Two (6.90%) did not survive to receive the HPSCs. Infusion was completed for 89 patients. Four patients receiving cryopreserved HPSCT had mild abdominal discomfort and dyspnea, which required temporary slowing of infusion. No serious adverse reactions were encountered [Table 2].
### Table 2: Comparison of present study with other published Indian literature

| Disease | Studies (Year) | Number of Patients | Patients Transplanted | Median Dose (x10^6/Kg) | Neutrophil Engraftment (Day) | Platelet Engraftment (Day) | Number engrafted (%) | 30 Day Survival (%) | 100 Day Survival (%) | Remarks |
|---------|----------------|--------------------|-----------------------|------------------------|-----------------------------|---------------------------|----------------------|-------------------|---------------------|---------|
| Total   | Present Study (2010-13) | 95 | 89 | 5 | 12 | 12 | 83/89 (92.25) | 82/89 (92.13) | 78/89 (87.64) |  |
| Autologous Group | Present Study (2010-13) | 66 | 62 | 4.63 | 11 | 11.5 | 58/62 (93.5) | 58/62 (93.5) | 57/62 (91.9) |  |
| Total Autologous | 228 | 228 | 2.80 | 11 | 12 | 233/228 (93.42) | 205/228 (89.91) | 199/228 (87.28) |  |
| MM      | Present Study (2010-13) | 52 | 51 | 5 | 11 | 11 | 50/51 (98.03) | 50/51 (98.03) | 49/51 (96.07) |  |
| Present Study (1990-2009) | 170 | 154 | 3.8 | 11 | 12 | 148/154 (96.10) | 146/154 (94.80) | 144/154 (93.52) |  |
| HL      | Present Study (2010-2013) | 6 | 5 | 3.6 | 13 | 12 | 5/5 (100) | 5/5 (100) | 5/5 (100) | HL & NHL data combined |
| Present Study (1990-2005) | 25 | 25 | 2.42 | 11 | 12 | 22/25 (88) | 32/44 (72.7) | 32/44 (72.7) |  |
| NHL     | Present Study (1990-2008) | 4 | 4 | 4 | 8 | 12 | 2/4 (50) | 2/4 (50) | 2/4 (50) |  |
| Present Study (1990-2005) | 19 | 19 | 2.42 | 11 | 12 | 10/19 (52.6) | 32/44 (72.7) | 32/44 (72.7) |  |
| Others  | Present Study (2010-2013) | 4 | 2 | 4.4 | 10 | 10 | 1/2 (50) | 1/2 (50) | 1/2 (50) | HL & NHL data combined |
| Allogenic Group | Present Study (2010-2013) | 29 | 27 | 5.8 | 12 | 13 | 25/27 (92.6) | 24/27 (88.9) | 21/27 (77.8) | 62.2 (34 months) |
| Total allogenic | V Nair Et al (2002-2010) | 114 | 114 | 3 | NA | NA | NA | NA | NA |  |
| AA      | Present Study (2010-2013) | 9 | 7 | 5 | 12.5 | 12.5 | 6/7 (85.71) | 6/7 (85.71) | 5/7 (71.4) | 68.75 (16 months) |
| Present Study (2002-2010) | 16 | 16 | 6.75 | 8.5 | 12.9 | NA | NA | NA | 75.6 (29 months) |  |
| V Nair Et al (2004-2010) | 41 | 41 | 2.3 | 10 | 15 | 39/41 (95.12) | NA | NA |  |
| ALL     | Present Study (2010-2013) | 10 | 10 | 6 | 12.5 | 12.5 | 10/10 (100) | 10/10 (100) | 8/10 (80) | 53.8 (51 months) |
| Present Study (2002-2010) | 13 | 13 | 6.4 | 11 | 13.6 | NA | NA | NA |  |
| V Nair Et al (2002-2010) | 6 | 6 | 5.3 | 10.5 | 12 | 6/6 (100) | 5/6 (83.33) | 5/6 (83.33) | 46.7 (58 months) |
| AML     | Present Study (2010-2013) | 30 | 30 | 7 | 12.3 | 14 | NA | NA | NA |  |
| Present Study (2002-2010) | 30 | 30 | 7 | 12.3 | 14 | NA | NA | NA |  |
| Others  | Present Study (2010-2013) | 4 | 4 | 6.7 | 12 | 13 | 3/4 (75) | 3/4 (75) | 3/4 (75) |  |

In 62 patients who were infused in the autologous group, 58 (93.5%) engrafted while four (6.5%) had engraftment failure. Similarly, in allogeneic group, of 27 patients, 25 (92.6%) engrafted and 2 (7.40%) had engraftment failure [Table 2]. The median time for neutrophil and platelet engraftment in autologous group was 11 and 11.5 days, respectively, while in allogeneic group was 12 and 13 days, respectively [Table 2].
The 30-day disease-free survival was 93.5% (n = 58) in autologous HPSCT and 88.9% (n = 24) in allogeneic HPSCT group. The 100-day survival rate was 91.9% (n = 57) in autologous group and 77.8% (n = 21) in allogeneic group [Table 2].

**DISCUSSION**

This was a retrospective study done in single center to find the patient survival outcomes in recipients of autologous and allogeneic HPSCSTs. In this study, mean age of the patients was 40 years, and the indications for which HPSCT was done in this study follow the pattern of other transplants studies from India. This study also acknowledges the fact that a few patients in autologous and 2 in allogeneic group succumb to their disease even before they are transplanted (before infusion). This brings forth the fact that these patients with hematological conditions have quite an aggressive disease and the disease per se, the chemotherapy, or waiting for the transplant (during conditioning) or a combination of these can take a toll. This is also supported by other published report.

The median dose of 4.63 × 10^6 CD34+ cells/kg of recipient body weight in autologous group and 5.8 × 10^6 CD34+ cells/kg in allogeneic group came in mean 1.52 and 1.14 harvests per donor, respectively. This was due to improved collection efficiency of harvest procedures in this study. Mean of 1.52 procedures in autologous group is lower than the mean procedures (2) as reported by Kumar et al. per patient to obtain CD34+ yield of 2.42 × 10^6 cells/kg of recipient body weight undergoing autologous blood stem cell transplantation. The improved collection efficiency in the present study was possibly because of large-volume leukapheresis (mean of 18.9 L in autologous and 6.9 L in allogeneic group) and better CD34+ cell monitoring before and during harvest.

The median CD34+ dose of 5 million cells/kg in the present study resulted in early engraftment in majority (83/89) of the cases. The median time for neutrophil and platelet engraftment in autologous group was 11 and 11.5 days, respectively, which was similar to Kumar et al. while median time for neutrophil and platelet engraftment in allogeneic group was 12 and 13 days, respectively, which was comparable to Nair et al. and Seth et al. Four of 89 patients had engraftment failure.

The overall survival at day-30 and day-100 close to 90% shows that with physical infrastructure such as HEPA rooms, trained personnel, and multidisciplinary approach in a new transplant program can have good patient survival outcomes. Since this is a new HPSCT program, better patient selection and newer drug regimens would have contributed to relatively good results. Five patients succumbed after engraftment, one in autologous group because of cardiac arrest on day 45, four in allogeneic group because of veno-occlusive disease (one patient) on day 14 and graft-versus-host disease (three patients) between days 30 and 100. The cause of mortality is similar to the published report.

In the autologous group, the patient survival in MM, HL, and NHL was similar to the publications by Kumar et al. Likewise, in the allogeneic group, the patient survival in aplastic anemia (AA), AML, and ALL is comparable with Nair et al. In addition, the patient survival in AA is in line with the publication of Seth et al.

**CONCLUSION**

This data analysis shows reasonably good results of HPSCSTs with majority of patients surviving at 30-day and 100-day follow-up. These results and its comparison with existing published reports reassure the robustness of the new HPSCT program and provide framework for designing patient counseling/education material and future outcome research.

**Acknowledgment**

We wish to acknowledge the conceptual inputs from Ms. Anjali Chaudhary, Dr. Geet Aggarwal, Mr. Ganesh Singh, Mr. Manish Singh, Dr. Pooya Sharma, and Dr. Padam Singh.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Thomas ED. Bone marrow transplantation: A review. Semin Hematol 1999;36:4 Suppl 7:95-103.
2. Forman SJ, Blume KG, Thomas ED, editors. Hematopoietic Cell Transplantation. 2nd ed. London, New York: Blackwell Scientific Publishers Inc.; 1998.
3. Coddock D. Haemopoietic stem-cell transplantation: Recent progress and future promise. Lancet Oncol 2000;1:227-34.
4. Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 2002;29:639-46.
5. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002;100:2374-86.
6. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
7. Körbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995;85:1659-65.
8. Russell JA, Bowen T, Brown C, Luider J, Ruether JD, Stewart D, et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hematopoietic cells. Bone Marrow Transplant 1996;18:501-5.
Demirer T, Gooley T, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 1996;88:2794-800.

Russell JA, Brown C, Bowen T, Luider J, Ruether JD, Stewart D, et al. Allogeneic blood cell transplants for haematological malignancies: Preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996;17:703-8.

Schmitz N, Bacigalupo A, Labopin M, Majolino I, Laporte JP, Brinch L, et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996;95:715-23.

Korbling M, Mirza N, Przepiorka D, Anderlini P, Chan KW, Champlin R. Clinical outcome in 112 patients following HLA-identical peripheral blood stem cell (PBSC). Blood 1997;10(Suppl. 1):224a-225a.

Miflin G, Russell NH, Hutchinson RM, Morgan G, Potter M, Pagliuca A, et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies – An analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997;19:9-13.

Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998;22:1145-51.

Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoj S, et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999;17:806-12.

Champlin RE, Schmitz N, Horowitz MM, Chaupis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Sources Working Committee and the European Group for Blood and Bone Marrow Transplantation (EBMT). Blood 2000;95:3702-9.

Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.

Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: A global perspective. JAMA 2010;303:1617-24.

Chandy M. Stem cell transplantation in India. Bone Marrow Transplant 2008;42 Suppl 1:S81-4.

Kumar L, Ganessian P, Ghosh I, Panda D, Gogia A, Mandhania S. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: Complications and outcome. Natl Med J India 2010;23:330-5.

Kumar L, Malik PS, Prakash G, Prabu R, Radhakrishnan V, Katyal S, et al. Autologous hematopoietic stem cell transplantation-what determines the outcome: An experience from North India. Ann Hematol 2011;90:1317-28.

Kumar L, Cyriac SL, Tejomurtula TV, Bahl A, Biswas B, Sahoo RK, et al. Autologous stem cell transplantation for multiple myeloma: Identification of prognostic factors. Clin Lymphoma Myeloma Leuk 2013;13:32-41.

Seth T, Kanga U, Sood P, Sharma V, Mishra P, Mahapatra M. Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients. Transplant Proc 2012;44:922-4.

Nair V, Sharma A, Das S, Sharma S, Grover N, Kaur J. Allogeneic hematopoietic stem cell transplantation: The Army hospital experience. Nati Med J India 2013;26:6-11.

Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012;120:468-72.

Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014;20:1262-73.

Sezer O, Possinger K, Metzner B, Illiger HJ, Wattad M, Heit W, et al. Optimal CD34(+) cell dose in autologous peripheral-blood-stem-cell transplantation. J Clin Oncol 2000;18:3319-20.

Mehta J, Mehta J, Frankurt O, Altman J, Evans A, Tallman M, et al. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009;50:1434-41.

Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34 + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-26.

Benz D, McCormack EM, Winer ES, Colvin GA, Quesenberry PJ. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007;82:463-72.

Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF. Recovery of viable CD34 + cells from cryopreserved hematopoietic progenitor cell products. Bone Marrow Transplant 2005;36:199-204.

Wingard JR, Gastineau DA, Leather HL, Snyder E, Szczepiorkowski ZM. Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians. Bethesda, Maryland: AABB; 2009.

Gajewski JL, Johnson VV, Sandler SG, Sayegh A, Klumpp TR. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008;112:3036-47.